SOURCE: Pegasus Pharmaceuticals Inc.

November 30, 2006 13:51 ET

Pegasus/HeartView's Screening Device for Heart Disease Receives Marketing Approval for European Union

PALM BEACH GARDENS, FL -- (MARKET WIRE) -- November 30, 2006 -- Pegasus/HeartView LLC (PINKSHEETS: PGUZ) today announced that they have received a CE Mark Approval for the marketing of their 6S Screening Device in Europe. The CE Mark Approval authorizes Pegasus to commence a comprehensive marketing effort throughout Europe and many other countries, which recognize the CE Mark Approval.

In November, Pegasus/HeartView LLC participated with one of its OEM European manufacturers in the world's largest medical trade fair, the MEDICA 2006 SHOW, in Dusseldorf, Germany (November 14th to 17th, 2006). Pegasus/HeartView demonstrated the 6S Heart Screening Device to hundreds of medical professionals and met with several potential European distributors who will participate in the marketing launch of the device, which is an advanced, rapid and accurate screening technology for early, non-invasive detection of heart disease.

Contact Information

  • For more information on the HeartVue 6S Device, please visit the Company's
    website at:
    www.pegasusbiosciences.com

    Contact:
    Paul Davey
    Investor Services
    (778) 389-0915 (Canada)
    paul@pegasusbiosciences.com

    Daniel P. Kesonen
    Chairman & CEO of Pegasus Pharmaceuticals Inc.
    Palm Beach, FL
    (561) 626-9901